Details of the Drug

General Information of Drug (ID: DMKOHC5)

Drug Name

Astegolimab

Synonyms

RG6149; MSTT1041A

Indication

Disease Entry	ICD 11	Status	REF
Chronic obstructive pulmonary disease	CA22	Phase 3	[1]
Asthma	CA23	Phase 2	[2]
------------------------------------------------------------------------------------

Drug Type

Monoclonal antibody

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-1 receptor-like 1 (IL1RL1)	TT4GZA4	ILRL1_HUMAN	Not Available	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05878769) A Phase III Open-Label Extension Study to Evaluate the Long-Term Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT02918019) A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Uncontrolled Severe Asthma. U.S.National Institutes of Health.
3	Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial. Lancet Respir Med. 2022 May;10(5):469-477.